World

US arrests Chinese scientist for smuggling biological materials

Jun 10, 2025

Washington [US], June 10: US authorities said they arrested a Chinese scientist at an airport on charges of smuggling biological material.
AP reported on June 10 that this was the second incident in a few days involving the smuggling of biological materials. The scientist was arrested on June 8 at the Detroit airport in Michigan (USA) after departing from China .
In court filings, the Federal Bureau of Investigation (FBI) said the biological samples seized involved several species of worms and required a government permit.
A few months ago, the same scientist was accused of transporting biological material to employees at a University of Michigan lab . She was pursuing an advanced degree at Huazhong University of Science and Technology in Wuhan, China. She planned to spend a year completing the project at the University of Michigan.
The FBI did not say whether the biological samples were dangerous, but Detroit prosecutor Jerome Gorgon Jr. said the smuggling posed a security threat. The scientist arrested on June 8 is currently in custody awaiting a hearing on June 11.
"The regulations governing the importation of biological material into the United States for research purposes are strict and clear. Such smuggling practices undermine the legitimate work of other scholars," the FBI said.
Last week, the US government charged two Chinese scientists with conspiring to smuggle a poisonous mushroom into the US. One, a scientist at the University of Michigan, is currently in custody, while the other returned to China last year.
Source: Thanh Nien Newspaper

More news

Infosys: Differentiated AI strategy and a sharp focus on value unlock propels 29% sequential growth in AI revenues

Bengaluru (Karnataka) [India], October 23: Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in AI-first business consulting and technology services, delivered $5,145 million in Q2 revenues, year on year growth of 1.5% and sequential growth of 1.2% in constant currency. Operating margin was stable at 21.0%. EPS growth was 8.7% year on year in rupee terms. TCV of large deal wins was $5.2 billion, with 62% net new. Robust Q2 large deal TCV at $5.2 billion with 62% net new; lays solid foundation for future growth. FY 27 revenue guidance revised to 1%-2% and margin guidance retained at 20%-22%.

Oct 23, 2026